NEW YORK (GenomeWeb) – Metamark Genetics said today that it has received Medicare coverage for ProMark, its proteomic test for prognosing early-stage prostate cancer.

Medicare Administrative Contractor Palmetto GBA issued a final local coverage decision for the test effective Oct. 10, 2016.

ProMark is a tool for identifying prostate cancer patients with likely non-aggressive forms of the disease that can be treated without surgery or radiation therapy. The test is intended for use in patients with biopsy Gleason Scores of 3+3 and 3+4.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.